Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MMP1 | P03956 | 2/20 | 0.31 |
| ▸ | MMP9 | P14780 | 2/20 | 0.31 |
| ▸ | MMP13 | P45452 | 2/20 | 0.31 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2472493 | 0.76 | NR4A2 (0.37) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL4768428 | 0.74 | MLYCD (0.34) | MLYCDHDAC1HDAC6TSHR | |
| SCHEMBL3530650 | 0.74 | NR4A2 (0.37) | KDM4EALDH1A1MEN1KMT2AHSD17B10 | |
| SCHEMBL3535482 | 0.70 | CA12 (0.35) | MLYCDHDAC1HDAC6MAPT | |
| SCHEMBL2478823 | 0.69 | MLYCD (0.36) | MLYCD | |
| SCHEMBL3537718 | 0.69 | ALOX5 (0.34) | KDM4EALDH1A1KMT2AHSD17B10CYP1A2 | |
| SCHEMBL4768305 | 0.68 | MLYCD (0.34) | MLYCDTSHR | |
| SCHEMBL3530598 | 0.67 | MLYCD (0.38) | ALDH1A1MEN1KMT2AMLYCDMAPT | |
| SCHEMBL2478961 | 0.66 | MAPT (0.35) | KDM4EMEN1KMT2AHSD17B10MAPT | |
| SCHEMBL19511326 | 0.63 | FFAR4 (0.46) | MEN1KMT2AMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2479175-A1 | Compounds and methods for treating dyslipidemia | Eli Lilly and Company (US) | 2012-07-25 | — | — | EP | disclosed |
| EP-1761522-B1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | LILLY CO ELI (US) | 2011-10-12 | — | — | EP | disclosed |
| US-7786108-B2 | Compounds and method for treating dyslipidemia | ELI LILLY AND COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | CHEN XINCHAO | 2010-08-12 | — | — | US | disclosed |
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | ELI LILLY AND COMPANY | 2007-10-18 | — | — | US | disclosed |
| EP-1761522-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2007-03-14 | — | — | EP | disclosed |
| WO-2006002342-A1 | COMPOUNDS AND METHODS FOR TREATING DYSLIPIDEMIA | ELI LILLY AND COMPANY (US) | 2006-01-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244095-A1 | S)-(3,5-Bistrifluoromethylbenzyl)-(1-cyclopentylmethyl-7-methyl-8-trifluoromethyl-2,3,4,5-tetrahydro-1H-benzo[b]azepin-5-yl)-(2-methyl-2H-tetrazol-5-yl)amine, for treating and/or preventing diseases related to abnormal cholesterol ester transfer protein activity such as atherosclerosis | CETP, APOB, MTTP | KDM4E 959/4885ALDH1A1 4410/4885MEN1 3703/4885 |
| US-20100204207-A1 | Compounds and Methods for Treating Dyslipidemia | APOB, LIPC, PCSK9 | KDM4E 2226/4885ALDH1A1 1541/4885MEN1 1329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.